9887 (9887) News
Track canonical SquawkNews coverage tagged to 9887, 9887. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Nanjing Leads Biolabs Co., Ltd. Wins Japan Orphan Drug Status for LBL-024
Nanjing Leads Biolabs said Japan’s MHLW granted Orphan Drug Designation to opamtistomig (LBL-024) for extrapulmonary neuroendocrine carcinoma, adding to prior U.S. and EU ODDs. The company notes potential development and
NEWS | Sep 28, 2026, 06:51 AM UTC
L
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
NANJING, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that opamtistomig (LBL-024), the Company’s proprietary PD—L1/4—1B
GEOPOLITICS | Sep 28, 2026, 06:51 AM UTC